

# Upcoming Joint CALL FOR PROPOSALS SPARK TEL AVIV - ICHILOV Mentoring Program

## Novel Therapeutics and Drug Repurposing Track

Advancing the Translation of Academic Discoveries to  
Clinical Practice



We are pleased to announce the launch of the 1<sup>st</sup> joint Call For Proposals of SPARK TEL AVIV, TAU, and Tel Aviv Sourasky Medical Center focused on advancing novel therapeutics and drug repurposing to the clinic. The nomination process opens in July 2025, so we encourage to explore potential collaborative projects and start preparing your application.

[SPARK TEL AVIV](#) is a mentoring program dedicated to accelerating scientific discoveries and expanding the societal impact of academic innovations. SPARK TEL AVIV is a member of the '[SPARK Global](#)' community, founded by Stanford University, and specializes in the field of translational medicine.

Our mission is to help researchers from TAU and TASMIC navigate the challenges of translating their research discoveries into new therapies. The upcoming 'Novel Therapeutics and Drug Repurposing track' is designed to support the transition from academic proof-of-concept studies to fully developed products, as well as preclinical and clinical trials that meet industry standards.

### The upcoming call will feature two categories:

1. Development of **NOVEL THERAPEUTICS** (small molecule or biologics), **MEDICAL DEVICES**, and **DIAGNOSTICS for UNMET MEDICAL NEEDS**.
2. **REPURPOSING OF EXISTING DRUGS** (approved or investigational drugs) for new indications that are outside the scope of the original medical indication.

Awarded projects will receive milestone-based funding for two years, up to \$100,000 per project/year. Funded projects will also receive ongoing mentorship, access to expert advisors, and educational program throughout all stages of product development.

### ELIGIBILITY AND PRIORITY

- Applications will be accepted from Active and Prolific Collaboration between Regular full-time TAU Researchers (NOT emeritus) and TASMIC Researchers (M.D./Ph.D.)
- Invited applications are for projects in the pre-translational phase, where proof of concept has already been established (e.g. in vivo results) and implementation is possible within 2 years.

### EVALUATION CRITERIA

Scope of UNMET CLINICAL NEED, NOVELTY of approach, TEAM suitability, Quality of DATA, Probability of COMMERCIALIZATION for Novel Therapeutics, FEASIBILITY (Budget and time)

### TIMELINE

- Nomination will open in **July 2025**. The submission deadline is **September 20, 2025**.
- Applied projects will be reviewed by an academic and clinical expert advisory team.
- Funding starts on **January 2026**.
- For questions and additional information, please contact:  
[moriakwiat@tauex.tau.ac.il](mailto:moriakwiat@tauex.tau.ac.il) // [hinbal@tauex.tau.ac.il](mailto:hinbal@tauex.tau.ac.il) // [halelis@tlvmc.gov.il](mailto:halelis@tlvmc.gov.il) // [galitco@tlvmc.gov.il](mailto:galitco@tlvmc.gov.il)